Viagenpumatucel-l clinical trials
Also written HS-110.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses viagenpumatucel-l is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Heat Biologics (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses viagenpumatucel-l is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerCompletedPhase 1/2Heat BiologicsNCT02439450Written as Viagenpumatucel-LHow we know
- A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerTerminatedPhase 2Heat BiologicsNCT02117024Written as Viagenpumatucel-LHow we know
- Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerWithdrawnPhase 2Heat BiologicsNCT01504542Written as HS110 vaccineHow we know
Given beside what is tested · 1 — viagenpumatucel-l is usual care or a partner of the new treatment
Codes
What other systems call viagenpumatucel-l · ClinicalTrials.gg INT014271
- UNII (FDA) 13H90KC831VIAGENPUMATUCEL-LOne source FDA
- NCI Thesaurus C61073Viagenpumatucel-LOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 13H90KC831 | VIAGENPUMATUCEL-L | One source FDA |
| NCI Thesaurus | C61073 | Viagenpumatucel-L | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.